In previous studies increased circulating levels of CD163 in patients with HCC and in diabetic patients with advanced NASH fibrosis, suggests CD163 as a biomarker for disease severity in NAFLD [74,56]. The gene discussed is CD163; the disease is hepatocellular carcinoma.